New Search

If you are not happy with the results below please do another search

32 search results for:

11

FFI generative AI framework & key services

/0 Comments/in
FFI generative AI framework & key services Ready to unlock the impact of #GenAI this summer? With over 18 months of diverse experience, FFI can rapidly support your organization in maximizing AI value creation. From strategy and governance to execution, we guide you through every step - including setting up your custom, private #GenerativeAI environment. [...]
12

Maximizing ROI in Pharma: A Deep Dive into AI Use Case Prioritization

/0 Comments/in
Maximizing ROI in Pharma: A Deep Dive into AI Use Case Prioritization The prioritization grid for generative AI use cases in the pharmaceutical industry provides a comprehensive overview of various use cases FFI-Ventures is working on today and within the last 18 months. The grid outlines the potential business impact, and technical feasibility of use [...]
13

FFI has a broad spectrum of capabilities

/0 Comments/in
FFI has broad spectrum of capabilities We're talking a lot about Hashtag#genAI but Hashtag#FFI goes beyond AI scaling in Pharma. We offer a unique blend of global and local expertise, combining innovative strategies with practical execution. Across Pharma, Medtech & Biotech functions, our approach and team delivers significant results & value-add. Discover how FFI can [...]
14

Ramping-up private gen AI within Pharma and Medtech organizations

/0 Comments/in
Ramping-up private gen AI within Pharma and Medtech organizations Especially for medical and commercial organizations, the integration of private bespoke generative AI solutions is becoming a game-changer. This blog post explores the strategic approach to implementing tailored AI solutions in the pharma industry, highlighting how FFI-Ventures can support organizations throughout this transformative journey. The step-wise [...]
15

Key Takeaways for Generative AI Adoption

/0 Comments/in
Key Takeaways for Gen AI Adoption With about 70 participants, the first Swiss AI Forum under the philosophy “from pharma for pharma” was a success and underlined the interest of Pharma and Biotech in tangible best practices to better achieve business objectives by applying generative AI solutions. For this occasion, the swiss health quality association [...]
16

Reflections on the Data+AI summit June 12/13, 2024

/0 Comments/in
Reflections on the Data+AI summit June 12/13, 2024 The Data+AI summit organized by Databricks in San Francisco yielded very valuable insights that supplement our learnings from work with more than 15 pharma and biotech organizations. Key themes that I took away: 1. Generative AI has confirmed potential, delivers value and can be a game changer [...]
17

Ways that generative AI can facilitate and accelerate work

/0 Comments/in
Ways that generative AI can facilitate and accelerate work The 502 page report by Stanford that came out earlier raises several points for consideration by knowledge workers. As the different generative ai models adapt and learn, they grow better at supporting and substituting tasks typically done by knowledge workers. While gaps persist, the question arising [...]
18

Sharing learnings: Unleashing the power of private generative AI in Medical Affairs

/0 Comments/in
Sharing learnings: Unleashing the power of private generative AI in Medical Affairs Today's blog post provides key learnings from the linkedin webinar held on May 28, 2024, offering a compelling overview into current applications of generative AI in Medical Affairs leveraging private or bespoke generative AI. Whether you're seeking to streamline operations, enhance accuracy, or [...]
19

Exploring JCA Timelines: Opportunities and Challenges

/0 Comments/in
Exploring JCA Timelines: Opportunities and Challenges for Pharma and Biotech In the evolving landscape of EU healthcare, the introduction of Joint Clinical Assessments (JCA) as part of the new Health Technology Assessment (HTA) regulations signifies a pivotal shift. These assessments are redefining Pharma and Biotech companies' approach to product evaluation and approval, presenting both significant [...]
20

Swiss Rare Disease Day 2024: Insights from the ProRaris Event

/0 Comments/in
Swiss Rare Disease Day 2024: Insights from the ProRaris Event at the Inselspital Bern On March 2nd, 2024, the event "Internationaler Tag der seltenen Krankeiten in der Schweiz" took place at the Auditorium Ettore Rossi, Inselspital Bern, to commemorate the 14th International Rare Disease Day in Switzerland. Organized by ProRaris, the symposium gathered around 150 [...]